- Home
- Publications
- Publication Search
- Publication Details
Title
TMB or not TMB as a biomarker: That is the question
Authors
Keywords
TMB, Immune checkpoints, PD-L1
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 163, Issue -, Pages 103374
Publisher
Elsevier BV
Online
2021-06-02
DOI
10.1016/j.critrevonc.2021.103374
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
- (2021) Cristina Valero et al. Nature Communications
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
- (2021) Benoit Rousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
- (2021) G.L. Banna et al. ESMO Open
- Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
- (2020) G. L. Banna et al. Clinical & Translational Oncology
- Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
- (2020) Mary A. Wood et al. Genome Medicine
- Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
- (2020) Giovanni Rossi et al. Cancers
- The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
- (2020) V. Prasad et al. ANNALS OF ONCOLOGY
- The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
- (2020) Amblessed E. Onuma et al. GENE EXPRESSION
- KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
- (2020) D. Marinelli et al. ANNALS OF ONCOLOGY
- Promising predictors of checkpoint inhibitor response in NSCLC
- (2020) Friedlaender Alex et al. Expert Review of Anticancer Therapy
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer
- (2019) Pushpinder Kaur et al. Scientific Reports
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
- (2019) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
- (2019) Aaron M. Goodman et al. Cancer Immunology Research
- How liquid biopsies can change clinical practice in oncology
- (2019) G Siravegna et al. ANNALS OF ONCOLOGY
- Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
- (2019) Hao-Xiang Wu et al. Annals of Translational Medicine
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature
- (2018) Katharina Schwarze et al. GENETICS IN MEDICINE
- Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
- (2018) Matteo Allegretti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
- (2018) Aaron M. Goodman et al. JAMA Oncology
- Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
- (2018) Siddhartha Devarakonda et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Cancer Neoantigens
- (2018) Ton N. Schumacher et al. Annual Review of Immunology
- APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
- (2018) Amélie Boichard et al. OncoImmunology
- Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
- (2017) Judith N. Müller et al. Journal of Thoracic Oncology
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
- (2017) Michaela Kotrova et al. Molecular Diagnosis & Therapy
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
- (2017) Amélie Boichard et al. OncoImmunology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
- (2016) R. M. Chabanon et al. CLINICAL CANCER RESEARCH
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
- (2016) Andrea Garofalo et al. Genome Medicine
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- High-Throughput Sequencing Technologies
- (2015) Jason A. Reuter et al. MOLECULAR CELL
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
- (2015) Luís Felipe Campesato et al. Oncotarget
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis, Optimization and Verification of Illumina-Generated 16S rRNA Gene Amplicon Surveys
- (2014) Michael C. Nelson et al. PLoS One
- Integrated analysis of germline and somatic variants in ovarian cancer
- (2014) Krishna L. Kanchi et al. Nature Communications
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Assuring the quality of next-generation sequencing in clinical laboratory practice
- (2012) Amy S Gargis et al. NATURE BIOTECHNOLOGY
- Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform
- (2011) Martin Kircher et al. NUCLEIC ACIDS RESEARCH
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started